![Johan Kördel](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Johan Kördel
Direttore/Membro del Consiglio presso Breye Therapeutics ApS
Posizioni attive di Johan Kördel
Società | Posizione | Inizio | Fine |
---|---|---|---|
Breye Therapeutics ApS
![]() Breye Therapeutics ApS Pharmaceuticals: MajorHealth Technology Breye Therapeutics ApS is a biopharmaceutical company based in Copenhagen, Denmark. The Danish company develops novel, oral ophthalmology drugs to address the needs of millions of patients suffering from deteriorating vision due to diabetic retinopathy (DR) or age-related macular degeneration (AMD). Breye Therapeutics' lead program with Danegaptide has a clinically de-risked safety profile and potential for a short and well-accepted clinical regulatory pathway. The company aims to provide less burdensome and more effective treatments for DR and AMD patients, which are currently treated with unpopular intravitreal injections directly into the eye. The company was founded in 2019, and the CEO is Ulrik Mouritzen. | Direttore/Membro del Consiglio | - | - |
Lundbeckfonden Ventures
![]() Lundbeckfonden Ventures Investment ManagersFinance Lundbeckfonden Ventures (Lundbeckfonden Ventures) is a venture capital firm wholly-owned by the Lundbeck Foundation. The firm was established in 2009 and is headquartered in Copenhagen, Denmark. | Investitore di Private Equity | 01/01/2010 | - |
Acacia Pharma, Inc.
![]() Acacia Pharma, Inc. Medical DistributorsDistribution Services Part of Eagle Pharmaceuticals, Inc., Acacia Pharma, Inc. distributes pharmaceutical products. The company is based in Dover, DE. | Direttore/Membro del Consiglio | 01/05/2022 | - |
Storia della carriera di Johan Kördel
Precedenti posizioni note di Johan Kördel
Società | Posizione | Inizio | Fine |
---|---|---|---|
Varmx BV
![]() Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Direttore/Membro del Consiglio | 01/07/2020 | 31/10/2021 |
AURA BIOSCIENCES, INC. | Direttore/Membro del Consiglio | 01/12/2017 | 31/10/2021 |
Atox Bio Ltd.
![]() Atox Bio Ltd. BiotechnologyHealth Technology Atox Bio, Inc. provides novel immune modulators for critically ill patients with severe infections. The firm discovers and develops novel immune modulators for critically ill patients with severe infections. Its main product is AB103, a novel immune modulator. The company was founded by Raymond Kaempfer and Gila Arad in 2003 and is headquartered in Ness Ziona, Israel. | Direttore/Membro del Consiglio | 01/07/2014 | 31/10/2021 |
DYSIS Medical Ltd.
![]() DYSIS Medical Ltd. Medical SpecialtiesHealth Technology DySIS Medical Ltd. designs, develops, manufactures, and markets medical imaging systems. Its imaging systems assist clinicians with non-invasive, in-vivo detection of cancerous and pre-cancerous lesions and provides tools to aid medical practitioners in the detection, grading, and documentation of cervical neoplasia. The company was founded by Costas Balas in 2002 and is headquartered in Livingston, the United Kingdom. | Direttore/Membro del Consiglio | 01/04/2013 | 31/10/2021 |
SPERO THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 01/06/2015 | 31/08/2018 |
Statistiche
Distribuzione geografica
Stati Uniti | 4 |
Danimarca | 3 |
Regno Unito | 2 |
Posizioni
Director/Board Member | 7 |
Private Equity Investor | 1 |
Settori
Health Technology | 7 |
Finance | 2 |
Distribution Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
AURA BIOSCIENCES, INC. | Health Technology |
SPERO THERAPEUTICS, INC. | Health Technology |
Aziende private | 6 |
---|---|
DYSIS Medical Ltd.
![]() DYSIS Medical Ltd. Medical SpecialtiesHealth Technology DySIS Medical Ltd. designs, develops, manufactures, and markets medical imaging systems. Its imaging systems assist clinicians with non-invasive, in-vivo detection of cancerous and pre-cancerous lesions and provides tools to aid medical practitioners in the detection, grading, and documentation of cervical neoplasia. The company was founded by Costas Balas in 2002 and is headquartered in Livingston, the United Kingdom. | Health Technology |
Lundbeckfonden Ventures
![]() Lundbeckfonden Ventures Investment ManagersFinance Lundbeckfonden Ventures (Lundbeckfonden Ventures) is a venture capital firm wholly-owned by the Lundbeck Foundation. The firm was established in 2009 and is headquartered in Copenhagen, Denmark. | Finance |
Atox Bio Ltd.
![]() Atox Bio Ltd. BiotechnologyHealth Technology Atox Bio, Inc. provides novel immune modulators for critically ill patients with severe infections. The firm discovers and develops novel immune modulators for critically ill patients with severe infections. Its main product is AB103, a novel immune modulator. The company was founded by Raymond Kaempfer and Gila Arad in 2003 and is headquartered in Ness Ziona, Israel. | Health Technology |
Acacia Pharma, Inc.
![]() Acacia Pharma, Inc. Medical DistributorsDistribution Services Part of Eagle Pharmaceuticals, Inc., Acacia Pharma, Inc. distributes pharmaceutical products. The company is based in Dover, DE. | Distribution Services |
Varmx BV
![]() Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Health Technology |
Breye Therapeutics ApS
![]() Breye Therapeutics ApS Pharmaceuticals: MajorHealth Technology Breye Therapeutics ApS is a biopharmaceutical company based in Copenhagen, Denmark. The Danish company develops novel, oral ophthalmology drugs to address the needs of millions of patients suffering from deteriorating vision due to diabetic retinopathy (DR) or age-related macular degeneration (AMD). Breye Therapeutics' lead program with Danegaptide has a clinically de-risked safety profile and potential for a short and well-accepted clinical regulatory pathway. The company aims to provide less burdensome and more effective treatments for DR and AMD patients, which are currently treated with unpopular intravitreal injections directly into the eye. The company was founded in 2019, and the CEO is Ulrik Mouritzen. | Health Technology |
- Borsa valori
- Insiders
- Johan Kördel
- Esperienza